DLL3 exhibits broad expression across neuroendocrine carcinomas (NECs), encompassing high-grade pulmonary, mammary, pancreatic, prostatic, and intestinal NECs, as well as low-grade gliomas and neuroblastomas, establishing its viability as a surface antigen for targeted therapies (51, 99). This evidence concerns the gene DLL3 and glioma.